Cayman Chemical

Our mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Company Website

Product Listing

SR 16832 5 mg  | ≥98%

Cayman Chemical

A dual-site covalent antagonist of PPARγ

More Information Supplier Page

×

SR 16832

SR 16832 1 mg  | ≥98%

Cayman Chemical

A dual-site covalent antagonist of PPARγ

More Information Supplier Page

×

SR 16832

SR 1824 25 mg  | ≥98%

Cayman Chemical

A non-agonist PPARγ ligand

More Information Supplier Page

×

SR 1824

SR 1824 10 mg  | ≥98%

Cayman Chemical

A non-agonist PPARγ ligand

More Information Supplier Page

×

SR 1824

SR 1824 5 mg  | ≥98%

Cayman Chemical

A non-agonist PPARγ ligand

More Information Supplier Page

×

SR 1824

SR 1824 1 mg  | ≥98%

Cayman Chemical

A non-agonist PPARγ ligand

More Information Supplier Page

×

SR 1824

SR 18292 25 mg  | ≥95%

Cayman Chemical

An inhibitor of PGC-1α

More Information Supplier Page

×

SR 18292

SR 18292 10 mg  | ≥95%

Cayman Chemical

An inhibitor of PGC-1α

More Information Supplier Page

×

SR 18292

SR 18292 5 mg  | ≥95%

Cayman Chemical

An inhibitor of PGC-1α

More Information Supplier Page

×

SR 18292

SR 18292 1 mg  | ≥95%

Cayman Chemical

An inhibitor of PGC-1α

More Information Supplier Page

×

SR 18292

SR 1903 10 mg  | ≥98%

Cayman Chemical

A modulator of RORγ and LXR receptors

More Information Supplier Page

×

SR 1903

SR 1903 5 mg  | ≥98%

Cayman Chemical

A modulator of RORγ and LXR receptors

More Information Supplier Page

×

SR 1903

SR 1903 1 mg  | ≥98%

Cayman Chemical

A modulator of RORγ and LXR receptors

More Information Supplier Page

×

SR 1903

SR 202 5 mg  | ≥95%

Cayman Chemical

An antagonist of agonist-induced PPARγ transcriptional activity

More Information Supplier Page

×

SR 202

SR 202 1 mg  | ≥95%

Cayman Chemical

An antagonist of agonist-induced PPARγ transcriptional activity

More Information Supplier Page

×

SR 202

SR 2211 10 mg  | ≥98%

Cayman Chemical

Selective inverse agonist of RORγ

More Information Supplier Page

×

SR 2211

SR 2211 5 mg  | ≥98%

Cayman Chemical

Selective inverse agonist of RORγ

More Information Supplier Page

×

SR 2211

SR 2211 1 mg  | ≥98%

Cayman Chemical

Selective inverse agonist of RORγ

More Information Supplier Page

×

SR 2211

SR 2595 10 mg  | ≥98%

Cayman Chemical

An inverse agonist of PPARγ

More Information Supplier Page

×

SR 2595

SR 2595 5 mg  | ≥98%

Cayman Chemical

An inverse agonist of PPARγ

More Information Supplier Page

×

SR 2595

SR 2595 1 mg  | ≥98%

Cayman Chemical

An inverse agonist of PPARγ

More Information Supplier Page

×

SR 2595

SR 27897 50 mg  | ≥98%

Cayman Chemical

A nonpeptide CCK1 antagonist

More Information Supplier Page

×

SR 27897

SR 27897 25 mg  | ≥98%

Cayman Chemical

A nonpeptide CCK1 antagonist

More Information Supplier Page

×

SR 27897

SR 27897 10 mg  | ≥98%

Cayman Chemical

A nonpeptide CCK1 antagonist

More Information Supplier Page

×

SR 27897

SR 27897 5 mg  | ≥98%

Cayman Chemical

A nonpeptide CCK1 antagonist

More Information Supplier Page

×

SR 27897

SR 3029 25 mg  | ≥98%

Cayman Chemical

An inhibitor of CK1δ and CK1ε

More Information Supplier Page

×

SR 3029

SR 3029 10 mg  | ≥98%

Cayman Chemical

An inhibitor of CK1δ and CK1ε

More Information Supplier Page

×

SR 3029

SR 3029 5 mg  | ≥98%

Cayman Chemical

An inhibitor of CK1δ and CK1ε

More Information Supplier Page

×

SR 3029

SR 318 25 mg  | ≥98%

Cayman Chemical

A dual inhibitor of p38α and p38β MAPKs

More Information Supplier Page

×

SR 318

SR 318 10 mg  | ≥98%

Cayman Chemical

A dual inhibitor of p38α and p38β MAPKs

More Information Supplier Page

×

SR 318

SR 318 5 mg  | ≥98%

Cayman Chemical

A dual inhibitor of p38α and p38β MAPKs

More Information Supplier Page

×

SR 318

SR 318 1 mg  | ≥98%

Cayman Chemical

A dual inhibitor of p38α and p38β MAPKs

More Information Supplier Page

×

SR 318

SR 3335 25 mg  | ≥95%

Cayman Chemical

A selective inverse agonist of RORα

More Information Supplier Page

×

SR 3335

SR 3335 10 mg  | ≥95%

Cayman Chemical

A selective inverse agonist of RORα

More Information Supplier Page

×

SR 3335

SR 3335 5 mg  | ≥95%

Cayman Chemical

A selective inverse agonist of RORα

More Information Supplier Page

×

SR 3335

SR 3335 1 mg  | ≥95%

Cayman Chemical

A selective inverse agonist of RORα

More Information Supplier Page

×

SR 3335

SR 3576 5 mg  | ≥98%

Cayman Chemical

A JNK3 inhibitor

More Information Supplier Page

×

SR 3576

SR 3576 1 mg  | ≥98%

Cayman Chemical

A JNK3 inhibitor

More Information Supplier Page

×

SR 3576

SR 3677 25 mg  | ≥95%

Cayman Chemical

A ROCK1 and ROCK2 inhibitor

More Information Supplier Page

×

SR 3677

SR 3677 10 mg  | ≥95%

Cayman Chemical

A ROCK1 and ROCK2 inhibitor

More Information Supplier Page

×

SR 3677

SR 3677 5 mg  | ≥95%

Cayman Chemical

A ROCK1 and ROCK2 inhibitor

More Information Supplier Page

×

SR 3677

SR 3677 1 mg  | ≥95%

Cayman Chemical

A ROCK1 and ROCK2 inhibitor

More Information Supplier Page

×

SR 3677

SR 4370 25 mg  | ≥98%

Cayman Chemical

An HDAC3 inhibitor

More Information Supplier Page

×

SR 4370

SR 4370 10 mg  | ≥98%

Cayman Chemical

An HDAC3 inhibitor

More Information Supplier Page

×

SR 4370

SR 4370 5 mg  | ≥98%

Cayman Chemical

An HDAC3 inhibitor

More Information Supplier Page

×

SR 4370

SR 4370 1 mg  | ≥98%

Cayman Chemical

An HDAC3 inhibitor

More Information Supplier Page

×

SR 4370

SR 4835 5 mg  | ≥98%

Cayman Chemical

A Cdk12 and Cdk13 inhibitor

More Information Supplier Page

×

SR 4835

SR 4835 10 mg  | ≥98%

Cayman Chemical

A Cdk12 and Cdk13 inhibitor

More Information Supplier Page

×

SR 4835

SR 4835 25 mg  | ≥98%

Cayman Chemical

A Cdk12 and Cdk13 inhibitor

More Information Supplier Page

×

SR 4835

SR 4835 50 mg  | ≥98%

Cayman Chemical

A Cdk12 and Cdk13 inhibitor

More Information Supplier Page

×

SR 4835